167 related articles for article (PubMed ID: 35829662)
1. Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors.
Thiis-Evensen E; Kjellman M; Knigge U; Gronbaek H; Schalin-Jäntti C; Welin S; Sorbye H; Del Pilar Schneider M; Belusa R;
J Neuroendocrinol; 2022 Jul; 34(7):e13176. PubMed ID: 35829662
[TBL] [Abstract][Full Text] [Related]
2. A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine Tumors.
Kjellman M; Knigge U; Welin S; Thiis-Evensen E; Gronbaek H; Schalin-Jäntti C; Sorbye H; Joergensen MT; Johanson V; Metso S; Waldum H; Søreide JA; Ebeling T; Lindberg F; Landerholm K; Wallin G; Salem F; Schneider MDP; Belusa R
Neuroendocrinology; 2021; 111(9):840-849. PubMed ID: 32721955
[TBL] [Abstract][Full Text] [Related]
3. Association between preoperative Vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET).
Andreasi V; Partelli S; Manzoni M; Muffatti F; Colombo B; Corti A; Falconi M
Pancreatology; 2019 Jan; 19(1):57-63. PubMed ID: 30470614
[TBL] [Abstract][Full Text] [Related]
4. The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age.
Partelli S; Muffatti F; Rancoita PMV; Andreasi V; Balzano G; Crippa S; Doglioni C; Rubini C; Zamboni G; Falconi M
Dig Liver Dis; 2019 May; 51(5):735-740. PubMed ID: 30723019
[TBL] [Abstract][Full Text] [Related]
5. C1QA and COMP: plasma-based biomarkers for early diagnosis of pancreatic neuroendocrine tumors.
Gorai PK; Bharti PS; Kumar S; Rajacharya GH; Bandyopadhyay S; Pal S; Dhingra R; Kumar R; Nikolajeff F; Kumar S; Rani N
Sci Rep; 2023 Nov; 13(1):21021. PubMed ID: 38030709
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors.
Mandair D; Khan MS; Lopes A; Furtado O'Mahony L; Ensell L; Lowe H; Hartley JA; Toumpanakis C; Caplin M; Meyer T
J Clin Endocrinol Metab; 2021 Mar; 106(3):872-882. PubMed ID: 33180939
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
8. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors.
Dam G; Grønbæk H; Sorbye H; Thiis Evensen E; Paulsson B; Sundin A; Jensen C; Ebbesen D; Knigge U; Tiensuu Janson E
Neuroendocrinology; 2020; 110(3-4):217-224. PubMed ID: 31578011
[TBL] [Abstract][Full Text] [Related]
9. Diagnosing pancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1 in daily practice.
van Beek DJ; Pieterman CRC; Wessels FJ; van de Ven AC; de Herder WW; Dekkers OM; Zandee WT; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IHM; Vriens MR; Valk GD
Front Endocrinol (Lausanne); 2022; 13():926491. PubMed ID: 36277719
[TBL] [Abstract][Full Text] [Related]
10. Synchronous or metachronous presentation of pancreatic neuroendocrine tumor versus secondary lesion to pancreas in patients affected by renal cell carcinoma. Systematic review.
Persano I; Parlagreco E; La Salvia A; Audisio M; Volante M; Buttigliero C; Scagliotti GV; Brizzi MP
Semin Oncol; 2022 Dec; 49(6):476-481. PubMed ID: 36759234
[TBL] [Abstract][Full Text] [Related]
11. The dilemma of "indeterminate" interpretations of pancreatic neuroendocrine tumors on fine needle aspiration.
Ahmed A; VandenBussche CJ; Ali SZ; Olson MT
Diagn Cytopathol; 2016 Jan; 44(1):10-3. PubMed ID: 26402138
[TBL] [Abstract][Full Text] [Related]
12. Immunophenotypic and molecular characterization of pancreatic neuroendocrine tumors producing serotonin.
Depoilly T; Leroux R; Andrade D; Nicolle R; Dioguardi Burgio M; Marinoni I; Dokmak S; Ruszniewski P; Hentic O; Paradis V; De Mestier L; Perren A; Couvelard A; Cros J
Mod Pathol; 2022 Nov; 35(11):1713-1722. PubMed ID: 35739266
[TBL] [Abstract][Full Text] [Related]
13. Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors.
Cui T; Hurtig M; Elgue G; Li SC; Veronesi G; Essaghir A; Demoulin JB; Pelosi G; Alimohammadi M; Öberg K; Giandomenico V
PLoS One; 2010 Dec; 5(12):e16010. PubMed ID: 21209860
[TBL] [Abstract][Full Text] [Related]
14. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.
Mohanty SK; Tiwari A; Bhardwaj N; Chuang F; Kim E; Lugo H; Yuan X; Diffalha SA; Peralta-Venturina M; Balzer B; Dhall D
J Clin Pathol; 2021 Sep; 74(9):582-588. PubMed ID: 32934105
[TBL] [Abstract][Full Text] [Related]
15. Value of diffusion-weighted magnetic resonance imaging in predicting World Health Organization grade in G1/G2 pancreatic neuroendocrine tumors.
Guo C; Zhuge X; Chen X; Wang Z; Xiao W; Wang Q
Oncol Lett; 2017 Jun; 13(6):4141-4146. PubMed ID: 28599415
[TBL] [Abstract][Full Text] [Related]
16. Is the Real Prevalence of Pancreatic Neuroendocrine Tumors Underestimated? A Retrospective Study on a Large Series of Pancreatic Specimens.
Partelli S; Giannone F; Schiavo Lena M; Muffatti F; Andreasi V; Crippa S; Tamburrino D; Zamboni G; Rubini C; Doglioni C; Falconi M
Neuroendocrinology; 2019; 109(2):165-170. PubMed ID: 31117106
[TBL] [Abstract][Full Text] [Related]
17. The Eighth Edition of the American Joint Committee on Cancer Distant Metastases Stage Classification for Metastatic Pancreatic Neuroendocrine Tumors Might Be Feasible for Metastatic Pancreatic Ductal Adenocarcinomas.
Wen J; Chen J; Liu D; Xu X; Fan M; Zhang Z
Neuroendocrinology; 2020; 110(5):364-376. PubMed ID: 31357196
[TBL] [Abstract][Full Text] [Related]
18. Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?
Luchini C; Lawlor RT; Bersani S; Vicentini C; Paolino G; Mattiolo P; Pea A; Cingarlini S; Milella M; Scarpa A
Curr Oncol Rep; 2021 Jul; 23(9):106. PubMed ID: 34269919
[TBL] [Abstract][Full Text] [Related]
19. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
[TBL] [Abstract][Full Text] [Related]
20. Plasma tryptophan pathway metabolites quantified by liquid chromatography-tandem mass spectrometry as biomarkers in neuroendocrine tumor patients.
Johansen SU; Hansen T; Nordborg A; Meyer R; Goll R; Florholmen J; Jensen E
J Neuroendocrinol; 2024 Mar; 36(3):e13372. PubMed ID: 38361341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
